Civil Litigation,
Intellectual Property
Oct. 6, 2017
Federal Circuit rejects injunction that favored Amgen
A federal appellate panel reversed a permanent injunction blocking the sale of a cholesterol drug on Thursday in a defeat for Thousand Oaks-based Amgen Inc.
An appellate panel on Thursday reversed a permanent injunction on the sale of a cholesterol drug, handing a defeat to Thousand Oaks-based Amgen Inc.
The U.S. Court of Appeals for the Federal Circuit overruled a decision by U.S. District Judge Sue Robinson of Delaware. The appeals court concluded that Robinson "misapplied" a 2006 U.S. Supreme Court ruling that makes it more difficult to get an injunction. The case was returned to Deaware for a new trial. Amgen ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In